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Abstract
Even though combined anti-retroviral therapy (cART) dramatically improves patient survival, they remain at a higher risk of
being afflicted with non-infectious complications such as cardiovascular disease (CVD). This increased risk is linked to
persistent inflammation and chronic immune activation. In this study, we assessed whether this complication is related to
HIV-derived ssRNAs inducing in macrophages increases in TNFa release through TLR8 activation leading to foam cell
formation. HIV ssRNAs induced foam cell formation in monocyte-derived macrophages (MDMs) in a dose-dependent
manner. This response was reduced when either endocytosis or endosomal acidification was inhibited by dynasore or
chloroquine, respectively. Using a flow cytometry FRET assay, we demonstrated that ssRNAs bind to TLR8 in HEK cells. In
MDMs, ssRNAs triggered a TLR8-mediated inflammatory response that ultimately lead to foam cell formation. Targeted
silencing of the TLR8 and MYD88 genes reduced foam cell formation. Furthermore, foam cell formation induced by these
ssRNAs was blocked by an anti-TNFa neutralizing antibody. Taken together in MDMs, HIV ssRNAs are internalized; bind TLR8
in the endosome followed by endosomal acidification. TLR8 signaling then triggers TNFa release and ultimately leads to
foam cell formation. As this response was inhibited by a blocking anti-TNFa antibody, drug targeting HIV ssRNA-driven TLR8
activation may serve as a potential therapeutic target to reduce chronic immune activation and inflammation leading to
CVD in HIV+ patients.
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Introduction
Increased risk of atherosclerosis and coronary heart disease
(CHD) is a well-recognized clinical problem in HIV-infected
patients [1,2]. HIV survivors in the United States aged 50 and
older have increased significantly with reduced AIDS-related
morbidity and mortality due to the introduction of combination
anti-retroviral therapy (cART) [3] however, these anti-retroviral
drugs failed to fully restore health in HIV-infected individuals. As
this population continues to age, CHD becomes increasingly an
important issue. This issue is closely associated with inflammation
that persists in cART-treated HIV+ individuals despite undetect-
able plasma viremia levels. Careful assessment of heightened CHD
risk in HIV+ patients is required to fully understand the
underlying causes. CHD incidence in HIV afflicted individuals is
three-fold greater than that in the general population [2,4].
However, it is not yet clear whether cardiovascular complications
are a consequence of HIV infection itself or due to long-term use
of HAART, or a combination of both. Interestingly, clinical
presentations of CHD in HIV infection are distinct from CHD
due to traditional risk factors. HIV patients are a decade younger
with a mean of 50 years, and unlike non-HIV patients tend to have
a single vessel affected rather than multiple vessels [5]. Moreover,
in HIV patients whose infection is controlled without receiving
cART (‘‘elite controllers’’), they also have more extensive carotid
narrowing than age-matched controls [6]. This association argues
for a direct effect by HIV-associated factors in inducing
cardiovascular disease [6]. HIV infection by itself is implicated
to associate with an increased risk of myocardial infarction based
on the results of the Strategies for Management of Anti-Retroviral
Therapy (SMART) study. Namely, patients undergoing episodic
antiretroviral therapy had an increased risk of cardiovascular
events than those undergoing continuous therapy [7]. Taken
together, these data show that HIV infection by itself markedly
contributes to atherosclerotic cardiovascular disease independent
of other traditional risk factors and cART.
The underlying mechanisms of early atherosclerosis in HIV
disease are not well understood, but similarly may be closely linked
to increased vascular inflammation. Toll-like receptors (TLRs) are
a superfamily of pathogen and viral constituent pattern recogni-
tion receptors (PRRs) that could play a central role in pathogen-
induced atherosclerosis [8]. TLRs 1, 2, 4, 5 and 6 are highly
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Associated with this change, activated NF-kB co-localizes in cells
within atheromatous plaques expressing TLR2 or TLR4 [9]. In
addition, functional studies confirmed that excised and cultured
human carotid plaques secrete TNFa and IFNc in response to
treatment with the TLR4 and TLR9 ligands: LPS and CpG DNA,
respectively [10]. Foam cell formation is implicated to be
dependent on TLR2 activation as suggested in a TLR2-deficient
mouse model infected with Chlamydia pneumonia [11]. In
addition, treatment of macrophages with either LPS (TLR4
agonist), CpG DNA (TLR9 agonist) promoted foam cell formation
[11–14]. These findings suggest that recognition of bacterial
pathogen associated molecular patterns (PAMPs) by TLRs is
involved in eliciting bacteria-induced foam cell formation.
Monocytes are precursors of macrophages within atheroscle-
rotic regions, that can transdifferentiate into lipid-laden foam cells
[15–17]. Macrophages play a critical role in the pathogenesis of
atherosclerosis. They are also a target of invading pathogens
including HIV that interfere with their immune function [18].
Plasma levels of a number of proinflammatory cytokines are
increased in HIV-infected persons [19], and their elevated levels
persist during HIV infection due to low-level viral replication, even
in patients receiving cART [20,21]. In addition, macrophages
associated with atherosclerotic lesions are a major source of both
proinflammatory cytokines including TNFa as well as chemokines
that could direct monocyte migration into these vascular lesions.
The inflammatory cascade activated by HIV has clear and diffuse
circumferential effects along the vascular endothelium, which are
distinct from accelerated atherosclerosis [22,23]. Therefore,
changes that occur in monocytes and macrophages during HIV
infection are likely to impact on the atherogenic process. HIV
interferes with the ability of macrophages to handle excessive
cholesterol by inhibiting cholesterol efflux, which could affect
initiation and progression of atherosclerotic events.
Using HEK-293 cells overexpressing TLR8 and clinically
relevant human healthy monocyte-derived macrophages (MDMs),
as well as primary alveolar macrophages (AMs), we show in this
report that HIV infection per se is sufficient to induce foam cell
formation. HIV-derived ssRNA binding to TLR8 induces foam
cell formation in part through inflammatory TNFa release. TNFa
involvement is likely since blocking TNFa down-regulates foam
cell formation. Foam cell induction by ssRNA is dependent on
dynamin-mediated endosomal uptake as well as intravesicular
acidification. Furthermore, ssRNA TLR8 binding and internali-
zation leads to TNFa release and foam cell formation since TLR8
gene silencing reduced this response. These results suggest that
proinflammatory factors including TNFa induced by HIV derived
ssRNA may activate monocytes to potentiate early atherogenic
processes in HIV+ individuals.
Materials and Methods
Reagents
ssRNA40/LyoVec and ssRNA41/Lyovec were purchased from
InvivoGen (San Diego, CA). Lipid A (the biologically active
component of LPS, and specific TLR4 ligand) from Escherichia
coli F583 Rd mutant, protease inhibitor cocktail and phorbol
myristic acid (PMA) were purchased from Sigma Chemical
Company (St Louis, MO). Bacterial lipopeptide (BLP) was from
EMD Millipore (Billerica, MA). Oxidized LDL was from Biomed-
ical Technologies, Inc. (Ward Hill, MA). Dynasore, and chloro-
quine were purchased from Calbiochem (San Diego, CA).
Paraformaldehyde solution (4% in Phosphate Buffered Saline) was
from Fisher Scientific. BODIPY 493/503 dye was from Life
Technologies (Carlsbad, CA). Saponin (molecular biology grade)
was from Sigma. Phosphate Buffered Saline without calcium or
magnesium was from Cellgro (Herndon, VA). Nef, was purchased
from Trinity Biotech (Wicklow, Ireland). The phosphorothioate
oligoribonucleotides, GU-rich ssRNA40 from LTR of HIV (59-
GCCCGUCUGUUGUGUGACUC-39, and GA-rich ssRNA41
(59-GCCCGACAGAAGAGAGACAC-39), were purchased from
Invivogen, San Diego, CA. Phosphorothioate oligoribonucleotide
conjugate Alexa 546-ssRNA40 (59-Alexa Fluor 546 GCCCGU-
CUGUUGUGUGACUC-39) was from Integrated DNA Technol-
ogies (Coralville, IA). The phosphorothioate oligoribonucleotides
antagomir99 (59-mCmAmAmCmAmGmAmCmGmGmGmC-
mAmCmAmCmAmCmUmAmC-39), HIV vmiR99 (59-PO4-
GUAGUGUGUGCCCGUCUGUmUmG-39) and HIV vmiR-
TAR (59-PO4-CUAACUAGGGAACCCACUmGmC-39) were
from Integrated DNA Technologies (Coralville, IA); ‘‘m’’ denotes
Figure 1. HIV replication and foam cell formation in MDM. A. MDMs were exposed to HIV particles, Ba-L strain (10 ng/0.1 Gag p42/10
6 cells
for 3 h and washed. p24 levels were assayed by ELISA. B. MDMs were infected with HIV for 4 days and foam cell formation was analyzed by BODIPY
staining. Data shown is a representative experiment with similar results from four different healthy uninfected subjects. *p,0.01 compared to mock
infected control.
doi:10.1371/journal.pone.0104039.g001
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in LyoVec according to the manufacturer’s instructions (Invivogen)
before each experiment.
Antibodies
Anti-TLR8-PE antibodies were purchased from Imgenex, (San
Diego, CA). Anti-MyD88, and b-actin antibodies were purchased
from Cell Signaling (Beverly, MA). Fluorescent conjugates of
monoclonal antibody against TLR8/CD288 (clone 44C143;
mouse IgG1/k), Alexa Fluor 488 conjugate of mouse IgG1/k
isotype control (clone MOPC-31C) were from Imgenex (San
Diego, CA). Cytokine ELISA kits were from R&D Systems
(Minneapolis, MN). HIV-1 p24 antigen ELISA kit was from
Zeptometrix (Franklin, MA).
Alveolar macrophages (AM)
To determine the clinical relevance of the study, select
experiments were carried out using human AM. Recruited healthy
subjects had no active pulmonary disease and normal spirometry.
They were confirmed to be HIV seronegative by ELISA and had
no known risk factors for HIV infection. Using standard
techniques, bronchoalveolar lavage (BAL) was performed to
obtain lung immune cells [24]. All procedures were performed
with written informed consent on adults following protocols
approved by Beth Israel Deaconess Medical Center Institutional
Review board and Committee for Clinical Investigations. Cells
were separated from the pooled BAL fluid and AM were isolated
[18]. AM were isolated by adherence to culture plates in medium
(RPMI 1640 containing 10% heat-inactivated fetal bovine serum,
2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin
and 250 ng/mL amphotericin B), and yielded cells that were .
98% viable as determined by trypan blue dye exclusion, and
demonstrated .95% positive nonspecific esterase staining.
Monocyte-derived macrophages (MDMs)
Healthy individuals were confirmed to be HIV seronegative by
ELISA and had no known risk factors for HIV infection. Using
standard techniques, venipuncture was performed to obtain
peripheral blood. All procedures were performed with written
informed consent on adults following protocols approved by Beth
Israel Deaconess Medical Center institutional review board and
Committee for Clinical Investigations. Healthy MDM was isolated
from buffy coat of healthy subjects using Percol Hypaque and
cultured for 7–10 days in medium (RPMI 1640 containing 10%
heat-inactivated fetal bovine serum, 2 mM glutamine, 100 U/mL
penicillin, 100 mg/mL streptomycin and 250 ng/mL amphoteri-
cin B) containing macrophage colony stimulating factor (M-CSF),
and non-adherent cells were washed away followed by addition of
fresh medium prior to experimentation.
Cells and Macrophage cell lines
HEK-293 stable cell line expressing full-length human TLR8
was from Imgenex. Macrophages were differentiated from human
promonocytic THP-1 (American Tissue and Cell Company,
Figure 2. HIV-derived ssRNA induces foam cell formation in a dose-dependent manner. MDMs were stimulated with different stimulants
for 24 h and stained with either Oil Red O staining (A–D) or BODIPY staining (E–J), and the bar graph shows integrated fluorescence intensities for
BODIPY in each cell of the confocal micrographs (K). The fluorescence intensity ratio (BODIPY/DAPI) from microplate assays shows the concentration
dependence of ssRNA-stimulated lipid accumulation (BODIPY) normalized to the number of cells (DAPI) in J. Data shown is a representative
experiment with similar results from four different healthy uninfected subjects. *p,0.01, **p,0.01 compared to vehicle control (LyoVec; NS). ssRNA
control (ssRNA 41) HIV-ssRNA (ssRNA 40).
doi:10.1371/journal.pone.0104039.g002
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phase, pelleted, resuspended and then incubated in complete
medium (RPMI 1640 containing 10% heat-inactivated fetal calf
serum (FCS), 2 mM glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin). To induce macrophage differentiation, THP-1
cells were incubated with 100 nM PMA at 37uC in a humidified
atmosphere containing 5% CO2 for 24 h. Adherent cells were
then washed three times with medium (to remove PMA) and
incubated (37uC, 5% CO2) in complete medium (without PMA)
for use in experiments.
Western blot analysis
Western blotting was performed as described [25]. Briefly,
adherent human macrophages were treated with indicated
reagents, washed 2x with ice-cold PBS (pH 7.4). Cells were lysed
in lysis buffer containing 25 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS and
protease inhibitor cocktail (Sigma Chemicals; St. Louis, MO),
placed on ice for 20 min. Cells were harvested by scraping,
followed by centrifugation at 4uC for 15 min at 14,000 rpm. Equal
amounts of cell lysates were subjected to SDS/PAGE and Western
blot analysis with designated antibodies and detected by enhanced
chemiluminescence (ECL) detection system (Amersham Biosci-
ences; Piscataway, NJ). Resolved bands were quantified by
densitometry (Amersham Biosciences; Piscataway, NJ).
Small Interfering RNA (siRNA)- mediated knockdown in
macrophages
To determine the functional relevance of TLR8 signaling
pathway in foam cell formation, RNAi-mediated knockdown of
TLR8 was performed using synthetic duplex RNA oligonucleo-
tides including On-Target Plus Smart Pool short interfering RNA
(siRNA) TLR8 (Thermo Scientific). Target sequences for TLR8
were GAACGGAAAUCCCGGUAUA, CAGAAUAGCAGGC-
GUAACA, GUGCAGCAAUCGUCGACUA, and CUUC-
CAAACUUAUCGACUA. The non-targeting irrelevant siRNA
(ON-TARGET plus Non-targeting siRNA#1 from Thermo
Scientific) was used as control. Macrophages were electroporated
with 100 nM siRNA using Amaxa Nucleofector system following
the manufacturer’s protocol (Amaxa). TLR8-mediated knockdown
was determined by Western blot probed with anti-TLR8, or flow
cytometry using anti-TLR8-PE 24–48 h after transfection.
Binding assay by flow cytometry – fluorescence
resonance energy transfer (FC-FRET)
HEK-293 cells expressing TLR8 were plated in 6-well plates
and grown in DMEM containing glucose (4.5 g/L), 10% FBS, L-
glutamine (4 mM), sodium pyruvate (1 mM), penicillin (100 units/
mL), streptomycin (100 mg/mL) and blasticidin (10 mg/mL) in
humidified atmosphere (37uC, 5% CO2). After aspiration, fresh
medium was applied (1.0 mL/well) without blasticidin. Oligonu-
cleotide ssRNA40-Alexa 546 was prepared at 50 mg/mL in
LyoVec (Invivogen, San Diego, CA) according to manufacturer’s
instructions and applied to wells (1.0 mg/mL) for 20 min at 37uC,
5% CO2. Medium was aspirated, and cells were treated with
trypsin/EDTA. Medium (2 mL) was applied to the cell suspension
and pelleted in centrifuge tubes. Cell pellets were re-suspended in
paraformaldehyde (4% in PBS) for 20 min at RT and then washed
once in PBS. Cell pellets were re-suspended and permeabilized in
PBS containing 0.1% saponin for 15 min at RT. Cells were
pelleted and supernatant aspirated. Cells were re-suspended in
PBS/0.1% saponin containing anti-TLR8 Alexa 488 or mouse
IgG1/k Alexa 488 (40 mg/mL) in the dark for 30 min at RT. Cells
were washed in PBS/0.1% saponin, centrifuged, re-suspended in
PBS containing 0.5% paraformaldehyde and placed in the dark at
4uC. Cells were analyzed using a SORP LSR II flow cytometer
system (BD Biosciences, San Jose, CA) configured with a solid state
50-mW 488-nm laser and a Coherent Compass 25-mW 561-nm
laser. For direct detection of labeled cells, Alexa 488 was excited
(488-nm laser) through the 505-nm longpass dichroic mirror and
emission detected through the 530/30 bandpass filter. Direct
detection of Alexa 546 was achieved by exciting with the 561-nm
laser with emission detected through the 585/42 bandpass filter.
For FRET assay, the 561-nm laser was disabled and its light path
physically blocked to ensure that FRET excitation was provided
exclusively by the 488-nm laser. FRET Donor (Alexa 488) was
detected using the 488-nm laser with emission through the 505-nm
longpass dichroic mirror and emission detected through the 530/
30 bandpass filter. The FRET Acceptor (Alexa 546) was detected
via 550-nm longpass dichroic mirror and emission through the
575/26 bandpass filter. Thus the presence of antibody-Alexa 488
and ssRNA-Alexa 546 was confirmed by direct excitation using
488-nm and 561-nm lasers, respectively. After disabling the 561-
nm laser, FRET was assessed by exciting with the 488-nm laser
and detecting emission by FRET Donor (Alexa 488) and FRET
Acceptor (Alexa 546). A minimum of 10,000 events was collected
for each sample, and data were analyzed using FCS Express Flow
Cytometry software (De Novo Software, Los Angeles, CA).
TLR analysis by flow cytometry
Cell surface expression of TLRs was determined by Epics XL
flow cytometer (Beckman/Coulter, Miami, FL) with laser power of
5.76 mW. The instrument was calibrated before each measure-
ment with standardized fluorescent particles (Immunocheck;
AMAC, Inc. Westbrook, ME). Fluorescence signals of the cells
were measured simultaneously by 3 photomultiplier tubes and
optical filters and shown as the mean of the log fluorescence
Figure 3. Induction of foam cell formation by HIV-derived
ssRNA is dependent on TNFa. MDMs were pre-treated with anti-
TNFa for 1 h followed by ssRNA incubation for 24 h and stained with
either Oil Red O staining (A) or BODIPY staining (B). Data shown is a
representative experiment with similar results from four different
healthy uninfected subjects. *p,0.05 compared to ssRNA control, TNF
+ IgG, **p,0.01 compared to ssRNA + IgG.
doi:10.1371/journal.pone.0104039.g003
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were incubated with an anti-TLR4 antibody on ice for 60 min,
washed three times, incubated with a FITC-conjugated secondary
antibody for 30 min on ice protected from light, fixed in Optilyse
(Beckman/Coulter, Miami, FL) at RT for 5–10 min, and analyzed
by flow cytometry. Human macrophages were first identified by
the characteristic forward and side scatter parameters on
unstained cells, and confirmed by staining with PE-conjugated
primary anti-human HLA-DR (Beckman/Coulter, Miami, FL).
Data were expressed as a mean relative fluorescence units (RFU)
and the percentage of cells staining positive. Isotype primary
conjugated antibodies served as a negative control. Samples were
prepared and analyzed in duplicate, and a minimum of 5,000 cells
was counted for each sample.
ELISA
After cell stimulation, supernatants were collected, centrifuged
to remove cellular debris, and assayed immediately or stored at –
80uC until assayed. Cytokine measurements were performed using
commercially available ELISA (R&D Systems, Minneapolis, MN)
following manufacturer’s instructions, and absorbance (450 nm)
was measured using an Emax ELISA plate reader with multi-point
data analysis by SoftMax Pro software (Molecular Devices,
Sunnyvale, CA). The detection limit for TNF-a was 15.6 pg/ml.
All measurements were performed in duplicate, and mean values
of the two measurements were used for statistical analysis.
Detection of lipid accumulation in macrophages
Accumulation of lipid droplets in macrophages and foam
cell formation. For detecting lipid accumulation in macro-
phages, lipophilic staining by Oil Red O and by BODIPY 493/
503 were performed [26,27]. Macrophages were incubated in
growth medium for incubation overnight on chamber slides (Nalge
Nunc International). Cells were then treated with ssRNA (2 mg/
ml) for 24 h. For Oil Red O staining, neutral lipids were stained
using 0.5% Oil-Red-O (Sigma) in isopropanol for 60 min. The
Oil- Red-O-stained lipids were morphologically evaluated by
microscopy. For BODIPY 493/503 fluorescence staining of
cholesterol ester, after incubation for indicated time, the cells
were washed twice in ice-cold PBS, followed by paraformaldehyde
fixation (2% in PBS) for 1 h at room temperature. The cells were
stained with BODIPY 493/503 working solution (10 mg/ml in
PBS) for 2 h at room temperature. The cells were rinsed twice with
PBS, counterstained with DAPI and mounted on the slides.
Micrographs were recorded using an SM 510 META inverted
confocal system (Carl Zeiss Microimaging, Inc.) using a 30-mW
argon ion laser (excitation wavelength, 488 nm) and emission
wavelengths from 505 to 635 nm. To measure lipid accumulation
in individual cells, total BODIPY staining intensity per cell was
measured from confocal micrographs using SigmaScan Pro 4.0
image analysis software (SPSS Inc). A second method to measure
lipid accumulation involved the fluorescence intensity ratio
(BODIPY/DAPI) in microplate assays using a Gemini EM
spectrofluorometer (Molecular Devices, Sunnyvale, CA). The
Figure 4. Dependence of HIV-derived ssRNA-induced foam cell formation and TNFa in macrophages on endocytosis and
endosomal acidification. MDMs were pretreated with 100 mM chloroquine or 50 mM dynasore for 1 h followed by incubation with 1 mg/ml HIV-
ssRNA for 24 h and stained with BODIPY and DAPI (A, C) and cell free supernatant analyzed for TNFa by ELISA and integrated fluorescence intensities
for BODIPY in each cell of the confocal micrographs (B). Data shown is a representative experiment with similar results from four different healthy
uninfected subjects. *p,0.05, **p,0.01 compared to vehicle control (LyoVec) or HIV-ssRNA alone. NS, non-stimulated vehicle control (LyoVec); CQ,
chloroquine; DY, dynasore.
doi:10.1371/journal.pone.0104039.g004
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emission 520 nm, cutoff 515 nm) to DAPI fluorescence intensity
(excitation 355 nm, emission 460 nm, cutoff 455 nm) is a readout
that measures lipid (BODIPY staining) and normalizes the signal
to the number of cells (DAPI nuclear stain).
Statistical Analysis
Group comparisons were performed using one-way ANOVA
followed by post hoc analysis using the Dunnett multiple
comparisons test. Calculations were performed with InStat3
(GraphPad Software, San Diego, CA) software package. Results
are given as mean 6 SEM. Statistical significance was accepted for
p,0.05.
Results
HIV infection is sufficient to induce foam cell formation in
monocyte-derived macrophages
Atherosclerosis incidence is consistently higher among HIV+
patients with or without cART treatment than that in the HIV-
negative population [28]. However, emerging data support the
hypothesis that HIV infection by itself promotes foam cell
formation [29,30,7]. To test this hypothesis, we assessed the
ability of HIV-1 to stimulate foam cell formation in monocyte-
derived macrophages. To determine whether HIV infection per se
causes foam cell formation, MDM were incubated with HIV-1
particles Ba-L strain (10 ng/0.1 ml Gag p24/10
6 cells), and cells
were washed three hours after incubation. Viral infection was then
assessed based on p24 measurements in the supernatant. Viral
replication starts at 4 days and peaks at 8 days post infection and
plateaus thereafter (Fig. 1A). Importantly, foam cell formation was
induced in HIV-infected cells as well as cells treated with a
protease inhibitor (PI) ritonavir measured by BODIPY staining
(Fig. 1B). These results show that HIV infection alone is sufficient
to induce foam cell formation in MDM.
HIV-1 ssRNA induces foam cell formation in monocyte-
derived macrophages human macrophages in a dose-
dependent manner
Soluble HIV proteins such as Nef, Tat, and Vpr have been
detected in the serum of HIV-infected patients [31,32]. They are
probably released into the circulation by infected or apoptotic
cells, which may interact with macrophages to drive an
inflammatory response. Recently, we have shown that HIV-
derived ssRNA40 induced TNFa release in macrophages [33]. We
assessed further whether uridine-rich HIV ssRNA is able to induce
foam cell formation using two independent methodologies (ie. Oil
red O staining and BODIPY). HIV-derived ssRNA is sufficient to
promote foam cell formation in macrophages as indicated by dose-
dependent increases in Oil Red O staining and BODIPY staining
(Figs. 2B, F, J). As a negative control, an inactive variant of GU
rich ssRNA was synthesized as AU-rich ssRNA. With this change,
its addition to macrophages failed to induce foam cell formation.
Their appearance was the same as that of unstimulated
macrophages (Figs. 2A, C, E, G). These effects were validated
by using instead oxidized LDL (ox-LDL), as a positive control,
which induces foam formation (Fig. 2D, I). Interestingly, Nef
protein (another molecular component of HIV) was also induced
foam cell formation in macrophages (Fig. 2H). In addition,
confocal BODIPY integrated intensity quantification is shown
Figure 5. HEK-TLR8 cells take up ssRNA40 (flow cytometry with dual laser excitation). (A) HEK cells expressing TLR8 were treated with
ssRNA40-Alexa 546 followed by fixation, permeablization and staining for TLR8 using anti-TLR8 Alexa 488 conjugate or isotype control IgG1/k Alexa
488. TLR8 detection is shown along the horizontal axis, and ssRNA40 Alexa 546 detection is shown along the vertical axis. Direct excitation (488 and
561 nm lasers) of both fluorophores (Alexa 488 and Alexa 546) allowed quantitation of cells staining positive for TLR8 (anti-TLR8-Alexa488) and cells
that had taken up ssRNA40-Alexa 546. Single-stranded RNA40 binds TLR8 (flow cytometry FRET assay). (B) HEK cells expressing TLR8 were unlabeled
or labeled with isotype control antibody (IgG1), anti-TLR8 Alexa 488 conjugate (anti-TLR8) and ssRNA40-Alexa 546 (ssRNA40). Upon excitation
at 488 nm, horizontal axes depict Alexa 488 emission (530 nm), and vertical axes show FRET emission (575 nm). Detection of TLR8 is shown in green.
Detection of ssRNA binding by TLR8 was measured using emission by the FRET acceptor, Alexa 546 (red). Alexa 546 fluorescence was also observed
(D–F, gold). A representative experiment is shown from three independent experiments with similar results.
doi:10.1371/journal.pone.0104039.g005
Figure 6. Dependence of foam cell formation in MDMs on TLR8 activation by HIV ssRNA. (A) Intracellular expression of TLR8 in MDMs.
MDMs which were incubated with PE-conjugated anti-TLR8 or isotype antibody control. Intracellular expression was determined by flow cytometry.
Representative profiles were similar in four independent experiments (n=4 subjects). (B) Functional silencing of human TLR8 leads to diminution of
foam cell formation in MDMs. BODIPY staining of MDMs after pretreatment with TLR8 siRNA or nonsilencing control. Cells were challenged with HIV
ssRNA or ssRNA control for 24 h. Bar graph shows integrated fluorescence intensities of BODIPY per cell of the confocal micrographs. Results are
representative of four independent experiments with similar results. **p,0.01 compared to NS siRNA + ssRNA41 control.
doi:10.1371/journal.pone.0104039.g006
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PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e104039Figure 7. Induction of foam cell formation in MDMs by HIV ssRNA is dependent on MyD88. MDMs were pretreated with MyD88 siRNA
and nonsilencing control. Cells were challenged with HIV ssRNA or ssRNA control and incubated for 24 h. Cell free supernatants were assayed for
TNFa by ELISA (A) and BODIPY staining (C). Western blot analysis of MyD88 after gene silencing with the use of MyD88 siRNA and nonsilencing siRNA
control. b-actin was used to monitor loading after stripping the membrane (B). Bar graph shows integrated fluorescence intensities of BODIPY per cell
of the confocal micrographs (D). A representative blot shows results from one experiment with similar results obtained in four independent
experiments.
doi:10.1371/journal.pone.0104039.g007
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to induce foam cell formation in macrophages and the effect is
specific because when uridine was replaced with adenine this
response is lost. These results suggest that increases in foam cell
formation by HIV ssRNA could be the result of HIV-induced
inflammation.
Blocking HIV ssRNA-mediated TNFa release inhibits foam
cell formation in MDMs
A critical early step in atherosclerosis is the migration of
monocytes into the developing atherosclerotic plaques and their
development into inflammatory lipid-laden foam cells [29]. We
recently demonstrated that signaling by HIV ssRNA induces
TNFa release in macrophages [33]. To demonstrate whether
inflammatory factors including TNFa mediate foam cell forma-
tion, induction of foam cell formation in MDMs was investigated
in the absence or presence of neutralizing anti-TNFa antibody.
Pre-treatment of human macrophages with anti-TNFa antibody
significantly reduced HIV ssRNA40 mediated foam cell formation
by 71% (Fig. 3). Activation of TNFa receptor induces robust foam
cell formation compared to unstimulated cells (Fig. 3), which was
inhibited in the presence of anti-TNFa antibody (Fig. 3). As a
positive control, Ox-LDL induced a robust foam cell formation
(Fig. 3). These data suggest that inflammatory factors such as
TNFa may also act on macrophages to cause them to become
foam cells and potentiate early atherogenic processes.
HIV-1 ssRNA40 induction of macrophage foam cell
formation is dependent on endosomal acidification and
endocytosis
We recently demonstrated that HIV-1 ssRNA signaling induces
TNFa release by macrophages that are dependent on TLR8
expression [33]. Next, we determined whether endosomal
acidification is required for HIV ssRNA-mediated foam cell
formation in MDMs. It has been shown that intracellular TLR
signaling is inhibited by chloroquine through inhibition of
lysosomal acidification [34]. Pretreatment of MDMs with chloro-
quine markedly inhibited HIV-ssRNA-mediated foam cell forma-
tion (Fig. 4A) and in a dose-dependent manner (Fig. 4C).
Interestingly, chloroquine inhibited TNFa release by MDMs
down to unstimulated levels (Fig. 4B), suggesting that induction of
TNFa by ssRNA40 plays a role in foam cell formation. Next, we
investigated the role of endocytosis in HIV-1 ssRNA40 induction
of foam cell formation in macrophages, in the presence or absence
of an inhibitor of the guanosine triphosphatase (GTPase) dynamin
(dynasore). TLR8 is expressed in the luminal aspect of the
endosomal membranes; therefore HIV-1 ssRNA40 must undergo
endocytosis in order to engage TLR8. Pre-treatment of human
macrophages with dynasore significantly reduced foam cell
formation induced by HIV ssRNA40 in MDMs in a dose-
dependent manner. Reduction of foam cell formation at 10 mM
was ,20% and at 50 mM ,50% (Fig. 4C), suggesting that
dynamin-mediated uptake of HIV ssRNA in MDMs contributes to
foam cell formation. Taken together, these data demonstrate in
MDMs that HIV-1 ssRNA induces foam cell formation through
endocytosis, endosomal acidification and TLR8 signaling.
HIV-1 ssRNA40 binds TLR8 protein measured by
fluorescence resonance energy transfer (FRET) assay
We recently reported that ssRNA40-stimulated TNFa release is
dependent upon its recognition and subsequent binding based on
the negative results obtained using siRNA-mediated knockdown of
TLR8 [33]. However, RNAi knockdown provides indirect
evidence of TLR8 involvement. We therefore sought direct
evidence of ssRNA40 binding to TLR8 using a fluorescence
resonance energy transfer (FRET) assay. The anti-TLR8 antibody
clone 44C143 (Imgenex, San Diego, CA) was raised against a
KLH-conjugated synthetic peptide from human TLR8 (residues
750–850), which includes an accessible a-helix (residues 781–789)
as possible epitope. Based on the published co-crystal structure of
CL097 (atom N3) bound to human TLR8 [35], solvent-exposed
residues (781–782, 785–786, 788–789) of the a-helix are 6563A ˚
away from the bound ligand CL097 (atom N3), which is
comparable to the Fo ¨rster energy transfer radius (Ro=64 A ˚) for
the FRET pair Alexa 488 and Alexa 546, [36]. A FRET pair at
that distance would have an expected FRET efficiency of
0.4760.07, which is consistent with the 0.50 FRET efficiency
reported for a flow cytometry FRET assay using oligonucleotide-
and fluorophore-conjugated antibodies [37]. Since a FRET assay
was theoretically feasible, we performed flow cytometry-FRET to
detect ssRNA40 binding to TLR8 in a recombinant cell system.
Accordingly, HEK-293 cells that had been stably transfected to
express human TLR8 were treated with ssRNA40 Alexa 546
conjugate. Cells were fixed, permeabilized and intracellular
antigen TLR8 detected using Alexa 488 conjugates of anti-
TLR8 antibody or isotype control.
To evaluate the proportions of labeled cells, we used dual
excitation (488 nm and 561-nm lasers). Direct excitation of both
fluorophores in conventional flow cytometry demonstrates that
HEK-TLR8 had specific labeling with 2.11% of cell population
positive for TLR8 (Fig. 5A, anti-TLR8 vs. IgG1 (green)) and
54.2% of cells had taken up the ssRNA40 Alexa 546 conjugate
(Fig. 5A, ssRNA40 (gold)). Double-positive cells (1.38% of
population were labeled for TLR8 (Alexa 488) and uptake of
ssRNA40 Alexa 546 (Fig. 5A, ssRNA40+ anti-TLR8 vs. IgG1+
ssRNA40 (red)).
Cells were further analyzed for FRET by flow cytometry
(Fig. 5B) with excitation at 488 nm and emission at 530 nm
(FRET Donor; Alexa 488) or 575 nm (FRET Acceptor; Alexa
546). Untreated cells show minimal background fluorescence
intensity for both TLR8 (Alexa 488 signal; horizontal axis of
Fig. 5B) and for ligand (Alexa 546; vertical axis of Fig. 5B). Isotype
antibody contributes little background fluorescence intensity
(Fig. 5B, IgG1). HEK-TLR8 cells stained with anti-TLR8
antibody Alexa 488 (FRET acceptor) indicate cells positive for
the TLR8 receptor (Fig. 5B, anti-TLR8 (green and red)), whereas
isotype control antibody contributes minimal background fluores-
cence intensity (Fig. 5B, IgG1). HEK-TLR8 cells that had taken
Figure 8. Foam cell formation is induced by HIV vmiR99 in
alveolar macrophages in a dose-dependent manner and is
inhibited by antagomir99. Alveolar macrophages were plated and
pretreated with different doses of antagomir99 followed different doses
of HIV vmiR99 and incubated for 24 h and stained with BODIPY 493/503
and DAPI. Results are representative of four independent experiments
with similar results.
doi:10.1371/journal.pone.0104039.g008
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showing a fraction of cells (7.46%) were fluorescent (Fig. 5B;
ssRNA40 (gold)), which was comparable to 7.39% of cells that had
taken up ssRNA40 Alexa 546 followed by staining with isotype
control antibody (Fig. 5B, ssRNA40+ IgG1 (gold)). Excitation
(488 nm) of HEK-TLR8 cells labeled with both FRET donor and
FRET acceptor exhibited total emission within the FRET gate in
1.92% of the cell population (Fig. 5B, ssRNA40+ anti-TLR8
FRET (red)), and subtracting the isotype control background
0.62% (Fig. 5B, ssRNA40+ IgG1 (red)) reveals specific FRET
emission in 1.3% of the total cell population. Thus, ,94% of
TLR8-positive cells that had taken up ssRNA40 demonstrated
detectable FRET signals indicative of ssRNA40 binding to TLR8
receptor in the flow cytometry FRET assay.
Foam cell formation in human macrophages is
dependent on TLR8 activation by HIV-1 ssRNA40
As HIV-1 ssRNA derived from Long Terminal Repeats
enriched in uridine activate TLR7 in murine dendritic cells and
TLR8 in human macrophages, we sought to determine whether
TLR8 is expressed in MDMs [38], and we confirmed by flow
cytometry analysis that TLR8 is expressed intracellularly in
MDMs (Fig. 6A). Accordingly, we next asked whether TLR8
engages HIV-1 ssRNA40 to induce foam cell formation in MDMs.
Foam cell formation induced by HIV-1 ssRNA was markedly
reduced in TLR8-silenced MDM compared to that in the non-
silencing control (Fig. 6B, middle and right panel). Furthermore,
an inactive ssRNA41 control failed to induce foam cell formation
in non-silenced cells (Fig. 6B, left panel). Taken together,
stimulation of foam cell formation by HIV-1 ssRNA40 in MDMs
is dependent on TLR8 activation.
Foam cell formation mediated by HIV-1 derived ssRNA40
in macrophages is dependent on induced MyD88
signaling
MyD88 is an adaptor protein that is recruited to mediate TLR8
signaling events leading to the release of cytokines such as TNFa
[33]. To determine the involvement of MyD88 in TLR8-linked
signaling in MDM cells, foam cell formation and TNFa release
were measured in the presence or absence of MyD88-targeted
gene silencing. Following exposure to non-silencing siRNA, HIV
ssRNA stimulated TNFa release in a dose-dependent manner
(Fig. 7A). Similarly, cells transfected with MyD88 siRNA also
elicited such a response, but TNFa release was reduced compared
to that in non-silenced cells (Fig. 7A). Similarly, TNFa release
induced by TLR2 agonist, BLP (10 mg/ml) was diminished in the
MyD88-silenced cells. Silencing of MyD88 gene resulted in ,65%
reduction of MyD88 protein (Fig. 7B). Furthermore, foam cell
formation was markedly reduced in MyD88 silenced cells (Fig. 7C,
D). To rule out off target effects, foam cell formation is similar in
non-silencing control compared to MyD88 silenced cells exposed
to Ox-LDL (Fig. 7C). Taken together, in MDMs TLR8 activation
by HIV-1 ssRNA stimulates TNFa release and foam cell
formation through a MyD88-dependent signaling pathway.
HIV-derived miRNA induces foam cell formation in a
dose-dependent manner and is inhibited by a specific
antagomir
Having established the effects of HIV ssRNA stimulation on
foam cell formation, we tested the effect of HIV-derived miRNA
on macrophage formation. MicroRNAs are a class of non-coding
RNAs consisting of processed products approximately 22 nucle-
otides in length with canonical function to regulate target gene
expression [39,40]. However, recent studies suggest that miRNAs
can even serve as physiological ligands of Toll-like receptors, a
function that is independent of their conventional role in post-
transcriptional gene regulation [41,42]. We examined published
Deep Sequencing data obtained from HIV-infected cells revealing
peaks of short RNA reads throughout the HIV genome [43], and
one of these peaks overlaps the ssRNA40 sequence. These GU-
rich tract is found in the HIV LTR (R and U5 regions of HIV-1
BaL strain) that encompasses a hot-spot of short RNA indicative of
possible mature microRNAs. Using UNAfold RNA-folding
software, characteristic shRNA structure was obtained including
vmiR-TAR [43], and in addition we identified two novel
candidate shRNAs, which we denote vmiR88 and vmiR99. These
candidate miRNAs were synthesized and tested for biological
activity such as foam cell formation in macrophages, and
sequences are shown in the methods section. Incubation of human
AM with vmiR-TAR (1 mg/ml) did not induce foam cell formation
compared to control (Fig. 8). In contrast, incubation with novel
vmiR99 resulted in a dose-dependent induction of foam cell
formation. Foam cell formation began at 0.01 mg/ml, and reached
a maximum level at 1 mg/ml (Fig. 8). Interestingly, this response
was inhibited by antagomir99, which has a completely comple-
mentary sequence of its target in a dose-dependent manner.
Similarly, vmiR88 also induced a robust foam cell formation
(Fig. 8). Taken together, in macrophages HIV-derived miRNA
can induce foam cell formation in a dose-dependent manner and
can be inhibited by a specific antagomir. These results demon-
strate that HIV-derived miRNAs can induce foam cell formation.
Discussion
In this study, we show in macrophages that HIV infection per se
is sufficient to induce foam cell formation through TLR8
activation leading to increases in TNFa release. Foam cell
formation mediated by HIV ssRNA appears to be driven by
inflammatory factors such as TNFa since blocking TNFa down-
regulates foam cell formation. Foam cell induction by ssRNA is
dependent on dynamin-mediated uptake as well as endosomal
acidification. Furthermore, induction of TNFa release by HIV
ssRNA is mediated by binding of ssRNA to TLR8, and gene
silencing of TLR8 as well as downstream signaling molecules such
as MyD88 reduced foam cell formation. These results suggest that
inflammatory factors including TNFa induced by HIV-derived
ssRNA may activate monocytes to potentiate early atherogenic
process in HIV+ individuals.
Chronic immune activation and inflammation have been
associated with an increased risk of non-AIDS co-morbidities
such as atherosclerosis even among patients on cART. The factors
leading to this phenomenon are complex, which includes
persistent viral replication coupled with cell death as well as
microbial translocation from the gastrointestinal tract. While viral
suppression reduces the degree of general immune dysfunction, a
chronic inflammatory state persists in many cases [44]. Our
finding that foam cell formation in macrophages is inhibited in the
presence of an anti-TNFa antibody is an extension of our report
describing induction of TNFa release from macrophages in
response to HIV ssRNA [33]. These responses agree with the
mechanism in which inflammation (i.e. TNFa release) could
account for the induction of foam cell formation in macrophages
in response to HIV ssRNA. This response is mediated by TLR8
binding to HIV ssRNA inducing TNFa release via MyD88
because silencing of this gene dramatically reduced foam cell
formation. These data suggest that HIV-derived ssRNA induces
differentiation of monocytes into foam cells by binding to its
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in macrophages and foam cell formation. This early step is critical
in the development of atherosclerosis [29].
This sole dependence on HIV infection to induce atherogenic
process is evident, since it was induced by exposure to HIV-
derived ssRNA TLR8 agonists irrespective of whether this
response occurred in healthy monocyte-derived macrophages or
primary alveolar macrophages. The fact that this response
occurred in HIV+ patients on cART suggests that a chronic
inflammatory state persists that elicits an increase in TNFa release
to drive foam cell formation. Interestingly, even though foam cell
formation is unrelated to whether or not patients received cART,
the subsequent underlying pathophysiological changes leading to
CVD development in HIV+ patients may differ from those not
affected with HIV. Such difference is possible since loci of the
pathological changes leading to CVD development are more
diffuse in non HIV+ patients than in those who are HIV+
irrespective of whether or not they received cART. The
underlying causes for this difference warrants further investigation.
A variety of different TLR subtypes are functionally expressed
in macrophages and are activated by pathogens, including bacteria
and viruses to induce inflammatory responses [45]. Endosomally
restricted TLRs including TLR8 induce inflammatory cytokine
release via MyD88 signaling pathway through interaction with
ssRNA derived from HIV that has a rich uridine sequence. In
addition, it was recently shown that exogenous addition of host
miRNAs can induce activation of TLR1 in NK cells [46],
suggesting that miRNAs can be recognized by both surface and
endosomal TLRs. TLR8 involvement in mediating TNFa release
and foam cell formation since function of this endosomal-delimited
receptor was compromised by inhibition of endosomal acidifica-
tion and dynamin-mediated endocytosis with chloroquine and
dynasore, respectively. Furthermore, TLR8 and MyD88 gene
silencing suppressed HIV ssRNA induction of foam cell formation.
Taken together, HIV ssRNA GU-rich oligonucleotide trigger
TLR8 activation to induce through MyD88-dependent signaling
pathway activation of TNFa release and ultimately foam cell
formation. Blockage of this response in a clinical setting may have
therapeutic value in suppressing HIV-1 mediated non-AIDS co-
morbidities such as atherosclerosis.
In this study, we showed that HIV ssRNA induced TNFa
release and foam cell formation could be ascribed to ssRNA
binding with TLR8, which is consistent with a recently published
report [47]. Foam cell formation appears to be dependent on
soluble factors such as TNFa, as our data suggest that blocking
TNFa ligation inhibits foam cell formation. These data suggest
that inflammatory factors including TNFa and monocytes
activation play a role in early atherogenic processes in HIV+
individuals.
In conclusion, this study demonstrates that HIV derived ssRNA
induces foam cell formation that is dependent on TNFa release.
HIV ssRNA elicits foam cell formation through ssRNA binding
with TLR8 and downstream MyD88 activation. MyD88 activa-
tion mediated by TLR8 is dependent on endosomal uptake of
HIV ssRNA and intravesicular acidification. A better understand-
ing of HIV ssRNA induction of inflammation and ultimately foam
cell formation could be a potential target for suppression of
chronic immune activation and inflammation.
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